Journal of Nuclear Medicine Technology (J Nucl Med Tech)

Publisher: Society of Nuclear Medicine (1953- ). Technologist Section, Society of Nuclear Medicine

Journal description

Published by the technologist section of the Society of Nuclear Medicine, the Journal of Nuclear Medicine Technology focuses entirely on the technology crucial to nuclear medicine. In peer-reviewed articles, every quarter the journal offers recent technically centered articles on imaging and instrumentation, radiopharmacy, quality assurance, radiation safety, and more. JNMT also serves as an invaluable continuing education tool, with teaching editorials, reviews of programs and certification updates, and continuing education articles.

Current impact factor: 0.00

Impact Factor Rankings

Additional details

5-year impact 0.00
Cited half-life 0.00
Immediacy index 0.00
Eigenfactor 0.00
Article influence 0.00
Website Journal of Nuclear Medicine Technology website
Other titles JNMT online., Journal of nuclear medicine technology
ISSN 0091-4916
OCLC 1787380
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details

Society of Nuclear Medicine

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • On author's personal website or departmental website
    • Must link to publisher version
    • Publisher copyright and source must be acknowledged with set statement (see policy)
  • Classification
    blue

Publications in this journal

  • Ashish Kumar Jha · Sneha Mithun · Abhijith M Singh · Nilendu C Purandare · Sneha Shah · Archi Agrawal · Venkatesh Rangarajan
    [Show abstract] [Hide abstract]
    ABSTRACT: Methods: Acceptance tests for a PET/CT scanner are a set of quality control tests performed after installation to verify various parameters specified by the manufacturer before utilizing the scanner for clinical use. We have performed the NEMA NU-2 2007 quality control test of this system and analyzed the results of continuous evaluation of gain calibration, timing resolution and energy resolution for a subsequent period of eighteen months. Results: Gemini TF 16 whole-body PET/CT scanner passed the entire NEMA NU-2 acceptance testing and there were not many fluctuations observed in energy and timing resolutions during this period of observation. Conclusion: Our study shows that Gemini TF 16 whole-body PET/CT scanner is able to perform excellently for the study period of eighteen months despite high volume work.
    No preview · Article · Feb 2016 · Journal of Nuclear Medicine Technology
  • Rohit Ranade · Sandip Basu
    [Show abstract] [Hide abstract]
    ABSTRACT: Aims and objectives: Assessment of renal toxicity profile of (177)Lu-DOTATATE based Peptide Receptor Radionuclide therapy (PRRT) in patients of Metastatic Neuroendocrine tumor (NET) with a single functioning kidney. Materials and methods: This was a retrospective analysis of NET patients, who had undergone PRRT with (177)Lu-DOTATATE at a large tertiary care centre. The patients selected for the study fulfilled the following criteria: (i) all patients were cases of somatostastin receptor (SSTR) positive neuroendocrine tumours who had received at least 3 cycles of PRRT with (177)Lu-DOTATATE and (ii) had a documented single functioning kidney. The selected patients were analyzed under the following parameters: (i) the patient characteristics, (ii) associated metastatic burden, (iii) renal parameters at diagnosis and during the course of therapy, (iv) evaluation of associated nephrotoxic factors. For renal assessment, following parameters were studied before each PRRT cycle: (i) glomerular filtration rate (GFR) estimated by (99m)Tc-DTPA renogram study, (ii) Effective Renal Plasma Flow (ERPF) by (99m)Tc-EC renogram study, (iii) blood urea and serum creatinine levels. Renal toxicity was evaluated using Common Terminology Criteria for Adverse Events v4.0 (NCI-CTCAE score). The percentage reduction in the GFR and ERPF for all patients was also assessed. Calculation of filtration fraction (FF) was undertaken to clarify whether there has been a relatively greater reduction in one of the two indices of renal function compared to the other. Results: At the time of analysis, six patients with single functioning kidney with metastatic NET received PRRT with (177)Lu-DOTATATE between 3-5 cycles and cumulative activity of 16.6 GBq to 36.2 GBq. Duration of follow-up ranged from 12 - 56 months. Overall toxicity profile (as per the NCI-CTCAE score) showed no patients had any acute renal toxicity. Three patients had no overall chronic renal toxicity; one patient had grade II chronic renal toxicity and two patients had grade I chronic renal toxicity level . All the patients who showed overall chronic renal toxicity showed compromised renal function at the onset (baseline chronic renal toxicity). Interestingly, the two patients with resultant grade I chronic renal toxicity level post-PRRT had grade II chronic renal toxicity before commencement of PRRT with gradual improvement over the subsequent cycles. One patient had grade II chronic renal toxicity before commencement of PRRT with transient worsening to grade III toxicity after first cycle PRRT with gradual improvement and return to basal levels post second cycle of PRRT (values revert back to the grade II toxicity grade). Only two patients showed reduction in GFR (one patient had 5.3% reduction whereas one patient had 13.84% reduction). Four patients showed a reduction in the ERPF (with one patient showing maximum reduction in ERPF it being 31.39% from basal ERPF) and all the four demonstrated rise in filtration fraction signifying that tubular parameters are more affected compared to the glomerular parameters. Conclusion: The preliminary results of this analysis show the feasibility of 177-Lu DOTATATE based PRRT in patients of NET with single functioning kidney, along with proper renal protection and dose fractionation. Further studies are required to assess the long term renal consequences of the changes in ERPF and FF parameters in these patients.
    No preview · Article · Feb 2016 · Journal of Nuclear Medicine Technology
  • Sandip Basu · Ketaki Utpat · Jyotsna Joshi
    [Show abstract] [Hide abstract]
    ABSTRACT: The (18)F-FDG-PET/CT imaging features in pulmonary inflammatory pseudotumor are illustrated, in a proven case both at initial diagnosis and in the context of early monitoring of corticosteroid therapy in this "great mimicker of malignancy". Complete surgical resection had to be finally undertaken in view of relative non-response to corticosteroid therapy advocated first line, though the patient had shown some symptomatic response and modest reduction of SUVmax. (18)F-FDG avidity in untreated cases of the pulmonary inflammatory pseudotumor has been quite characteristic and may be potentially utilized to evaluate early response to administered non-surgical treatment and also detect residual disease/recurrence following therapeutic intervention of this IgG4 related disease.
    No preview · Article · Feb 2016 · Journal of Nuclear Medicine Technology
  • Christopher Davin Sanders · Jared D Kirkland · Ely A Wolin
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary hyperparathyroidism is predominantly caused by a single parathyroid adenoma (1). Knowledge of normal and ectopic locations of parathyroid glands is crucial to help guide surgeons who plan targeted unilateral parathyroidectomy to reduce surgical time and risk. We describe a female patient with clinical primary hyperparathyroidism who underwent a failed initial parathyroidectomy, with subsequent imaging localizing an ectopic parathyroid adenoma in the carotid sheath.
    No preview · Article · Feb 2016 · Journal of Nuclear Medicine Technology
  • Nikita Sampathirao · Sandip Basu
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypergastrinemia is a prominent feature of a segment of gastroenetropancreatic neuroendocrine tumours, the gastrinomas, mostly occurring in the gastrinoma triangle. Hypergastrinemia due to a thoracic NET is a very rare occurrence with paucity of literature elucidating the same. We report a case of thoracic NET who had initially presented with symptoms of peptic ulcer disease of 3 years duration. On evaluation, the fasting serum gastrin levels were raised. Conventional imaging modalities and endoscopic evaluation did not identify the location of possible gastrinoma or any other mass in the abdomen. In view of hypergastrinemia, somatostatin receptor (SSTR) targeted imaging with (68)Ga-DOTATATE PET/CT was undertaken which showed a SSTR expressing paravertebral para-aortic mass (next to thoracic aorta) in the left lung. The mass was excised and the histopathology was suggestive of metastatic neuroendocrine tumour (Mib1 labeling index of 2%). The present case underscores the importance of (68)Ga-DOTATATE PET-CT in both detecting and characterizing the causative lesion missed on ceCT, that was not easily amenable to a biopsy.
    No preview · Article · Feb 2016 · Journal of Nuclear Medicine Technology

  • No preview · Article · Jan 2016 · Journal of Nuclear Medicine Technology
  • Source

    Preview · Article · Sep 2014 · Journal of Nuclear Medicine Technology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Incidental findings on low-dose CT images obtained during hybrid imaging are an increasing phenomenon as CT technology advances. Understanding the diagnostic value of incidental findings along with the technical limitations is important when reporting image results and recommending follow-up, which may result in an additional radiation dose from further diagnostic imaging and an increase in patient anxiety. This study assessed lesions incidentally detected on CT images acquired for attenuation correction on two SPECT/CT systems. Methods: An anthropomorphic chest phantom containing simulated lesions of varying size and density was imaged on an Infinia Hawkeye 4 and a Symbia T6 using the low-dose CT settings applied for attenuation correction acquisitions in myocardial perfusion imaging. Twenty-two interpreters assessed 46 images from each SPECT/CT system (15 normal images and 31 abnormal images; 41 lesions). Data were evaluated using a jackknife alternative free-response receiver-operating-characteristic analysis (JAFROC). Results: JAFROC analysis showed a significant difference (P < 0.0001) in lesion detection, with the figures of merit being 0.599 (95% confidence interval, 0.568, 0.631) and 0.810 (95% confidence interval, 0.781, 0.839) for the Infinia Hawkeye 4 and Symbia T6, respectively. Lesion detection on the Infinia Hawkeye 4 was generally limited to larger, higher-density lesions. The Symbia T6 allowed improved detection rates for midsized lesions and some lower-density lesions. However, interpreters struggled to detect small (5 mm) lesions on both image sets, irrespective of density. Conclusion: Lesion detection is more reliable on low-dose CT images from the Symbia T6 than from the Infinia Hawkeye 4. This phantom-based study gives an indication of potential lesion detection in the clinical context as shown by two commonly used SPECT/CT systems, which may assist the clinician in determining whether further diagnostic imaging is justified.
    No preview · Conference Paper · Jun 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To investigate the minimal required radioactivity and corresponding imaging time for reliable semi-quantification in PET-CT imaging to perform useful and comparable imaging studies in pursuit of as low as reasonably achievable (ALARA) in dose reduction. Materials and methods: We performed (18)F-FDG PET-CT study using a Jaszczak ECT phantom containing spheres of diameters (3.4, 2.1, 1.5, 1.2, 1.0 cm) filled with a fixed concentration of 165 kBq/ml and background of 23.3 kBq/ml at multiple time points over 20 hours of radioactive decay. The images were acquired for 10 minutes in a single bed position at each of 10 half-lives of decay using 3D list mode in a hybrid GE Discovery 690 PET-CT scanner. The images were reconstructed in 1, 2, 3, 4, 5, and 10 minutes per bed using ordered-subset expectation maximum (OSEM) algorithm with 24 subsets and 2 iterations with a gaussian 2-mm filter using an AW workstation (GE Healthcare) equipped with version 4.5 software. The maximum and average standardized uptake values (SUV) of each sphere were measured. Results: The minimal required activity concentration for precise SUVmax quantification in spheres (±10%) was determined to be 1.8 kBq/ml for 10 minutes, 3.7 kBq/ml for 3-5 minutes, 7.9 kBq/ml for 2 minutes, and 17.4 kBq/ml for 1 minute of acquisition per bed position. The minimal required value for the product of activity concentration and acquisition time per bed position was determined to be 10-15 kBq/ml*min for reproducible SUV measurement within the spheres without overestimation. Using the total radioactivity and count rate from the entire phantom, the minimal required values for the product with time per bed position was determined to be 17 MBq*min and 100 kcps*min, respectively. Conclusion: Our phantom study determined a threshold for minimal radioactivity and acquisition time for precise semi-quantification in FDG PET imaging that can serve as a guide in pursuit of achieving ALARA.
    No preview · Conference Paper · Dec 2013

  • No preview · Article · Dec 2013 · Journal of Nuclear Medicine Technology

  • No preview · Article · Dec 2012 · Journal of Nuclear Medicine Technology

  • No preview · Article · Dec 2012 · Journal of Nuclear Medicine Technology

  • No preview · Article · Sep 2012 · Journal of Nuclear Medicine Technology

  • No preview · Article · Sep 2012 · Journal of Nuclear Medicine Technology

  • No preview · Article · Mar 2012 · Journal of Nuclear Medicine Technology

  • No preview · Article · Mar 2012 · Journal of Nuclear Medicine Technology

  • No preview · Article · Mar 2012 · Journal of Nuclear Medicine Technology

  • No preview · Article · Mar 2012 · Journal of Nuclear Medicine Technology